# PreOmics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/preomics

- Industry: Biotechnology
- Headquarters: Munich, Germany
- Website: www.preomics.com
- Total disclosed funding: $3.8M
- Latest round: Series A (Dec 11, 2018)
- Investors on record: 2

## About

PreOmics GmbH provides advanced proteomics solutions, focusing on efficient protein and peptide sample preparation for mass spectrometry analysis. Its products enhance research workflows, offering reliable results for scientific applications.Founded in 2016 and headquartered in Munich, Germany, PreOmics GmbH specializes in proteomics solutions. The company has made three deals to date, with the most recent on January 18, 2022. In this round, Bruker Corporation invested EUR 13.500 mn during the Series B funding, bringing the total amount raised to EUR 13.500 mn and valuing the firm at EUR 16.537 mn. Garwin Pichler serves as both the Founder and CEO, leading the company in its strategic developments.PreOmics GmbH specializes in advanced proteomics solutions, particularly in protein and peptide sample preparation for mass spectrometry (MS) analysis. Their flagship product, the PreOmics® iST kit, includes all necessary reagents, allowing researchers to streamline workflows and achieve results in as little as 4.5 hours of hands-on time. Additional offerings, such as the iST-NHS kit, are compatible with popular labeling methods like TMT and iTRAQ. The ENRICH family enhances the preparation of biological fluids, catering to research institutions and pharmaceutical companies across North America, Europe, and Asia, improving throughput and sample quality for biomarker discovery and proteomic analysis.PreOmics GmbH generates revenue through the sale of specialized proteomics kits and automation systems to academic and industrial clients. These transactions occur through B2B partnerships, allowing clients to procure products directly to support their research. Key products include ENRICH-iST kits and automated processing platforms, which enhance reliability for large-scale sample analysis. Customers typically make one-time purchases or establish ongoing supply agreements for access to essential reagents and technologies, integrating PreOmics solutions into their workflows.Following the most recent funding round on January 18, 2022, where Bruker Corporation acquired a stake in PreOmics GmbH, the company plans to invest in R&D and bolster its sales and marketing efforts. Future initiatives include the development of new products and expansion into targeted geographic markets, with a focus on enhancing its presence across various regions. These strategic efforts aim to capitalize on the latest funding of EUR 13.500 mn to drive growth and innovation.

## Funding rounds

- Series A, Dec 11, 2018, $3.8M — High-Tech Gruenderfonds, Think.Health Ventures

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- Think.Health Ventures (https://capitalatlas.ai/funds/think-health-ventures) — Series A